Evolving Role of Empagliflozin in Cardio-Renal Metabolic(CRM) Management

Overview

Course Description

Participants will gain an in-depth understanding of the evolving role of Empagliflozin in the management of cardio-renal metabolic (CRM) conditions. The EMPA Kidney Study, a landmark clinical trial, will be the focal point of discussion, highlighting its implications for the broad population of patients with chronic kidney disease (CKD). By examining the interconnectivity of the cardio-renal-metabolic systems, participants will reinforce their knowledge of the mutual influence of cardiovascular, renal, and metabolic diseases on each other.

What you will learn

By the end of this training, it is hoped that participants will learn:

1.The evolving role of Empagliflozin in the management of cardio-renal metabolic (CRM) conditions, with a focus on its implications for patients with chronic kidney disease (CKD).

2.To recognize the interconnectivity of cardiovascular, renal, and metabolic diseases, and the mutual influence they have on each other in the context of CRM management.

3. To familiarize participants with the latest guidelines and recommendations from reputable organizations, such as the AHA, ESC, and ADA, for the comprehensive management of kidney disease and its co-morbidities, including type 2 diabetes (T2D) and heart failure (HF).

4. Insights into the mechanism of action of Empagliflozin, particularly its inhibition of sodium-glucose co-transporter 2 (SGLT2) in the kidneys, and its impact on cardio-renal-metabolic outcomes.

5.To identify practical considerations and potential challenges in incorporating Empagliflozin into the treatment regimen for patients with cardio-renal-metabolic conditions, including dosage adjustments based on renal function, monitoring for volume depletion, and assessment of genitourinary infections.